Living With AARS2: Trajectory, Fertility, and Planning
At a Glance
People with AARS2-related leukoencephalopathy can remain stable for years or decline more quickly, so regular checks of memory, movement, and independence are important. Fertility and family planning should be discussed early with reproductive, genetic, and neurologic specialists.
Living with AARS2-related leukoencephalopathy means navigating a path that is uniquely yours. Because this condition is so rare, there is no “standard” timeline, but understanding the possibilities can help you and your family prepare for the future with clarity and compassion [1][2].
The Variability of Progression
One of the most challenging aspects of this diagnosis is its unpredictability. Researchers have documented a wide range of experiences in reported cases, though natural-history data are insufficient to provide population life-expectancy estimates:
- Reported Stability: Some individuals have been reported to remain functionally stable for long periods (e.g., one report noted stability over 9 years) with very little change in daily abilities [2].
- Rapid Change: Other reports describe a “plateau” where symptoms stay the same for years, followed by a period of more rapid decline—sometimes over just 12 months—where extensive caregiving support is needed [3].
- Long-term Survival: While it is a progressive condition, survival into the late 50s has been documented in individual case reports [4].
Because the pace varies, these reports are examples, not a forecast of your specific course. Your care team will rely on “functional reassessments”—regular check-ins to measure memory, walking, and ability to care for yourself—ensuring that supports like physical therapy or home modifications are added at the right time [5][6].
Fertility and Family Building
For many people with ovaries, the diagnosis of Premature Ovarian Insufficiency (POI) comes as a shock. It is important to know that while natural conception is rare (estimated at 5-10% in general POI, though AARS2-specific data are limited), it is not impossible [7][8].
If you are hoping to build a family, prompt individualized assessment with a reproductive endocrinologist is recommended:
- Egg or Embryo Freezing: If the diagnosis is caught early, cryopreservation may be an option, though established POI may leave few or no usable follicles [9][10].
- Donor Options: Using donor eggs or donor embryos is an established path for many women with POI [11][12].
- Adoption: Many families find this a rewarding path to parenthood.
- Preconception Team: It is vital to discuss the “safety” of pregnancy with a multidisciplinary team (neurology, cardiology, maternal-fetal medicine) given your neurological function and support needs [11].
Genetic Risks for the Family
AARS2-related disease is autosomal recessive. This means:
- For Children: If you have the condition, you will pass one pathogenic AARS2 variant to every biological child. Whether they develop the disease depends on whether your partner is also a carrier. If your partner is a carrier, each pregnancy has an approximately 50% chance of the child being affected and a 50% chance of being a carrier. If your partner is not a carrier, the children will generally be carriers but not affected [1][13]. (A partner’s carrier risk varies with ancestry and family history).
- Family Planning Options: A genetic counselor can discuss options like Preimplantation Genetic Testing for Monogenic disease (PGT-M) or prenatal diagnosis where appropriate [1].
- For Siblings: If both biological parents are carriers, each full sibling of an affected person has a 25% chance of having the condition [1][14]. Family members can undergo genetic carrier testing [15][16].
Caring for the Caregiver and Daily Life
If you are caring for someone with AARS2-related disease, your well-being is just as important as the patient’s.
- Daily Accommodations: You may eventually need cognitive aids, workplace accommodations, driving safety reassessments, and disability benefits.
- Plan Early: Because the disease can affect memory and decision-making, it is helpful to have “advance care” conversations early. This includes choosing a healthcare proxy and discussing preferences while the patient can fully participate [17][18].
- Functional Needs: As the disease progresses, you may need to reassess home safety (installing grab bars or ramps) and look into “respite care”—short-term relief for you to prevent burnout [18][6].
- Emotional Support: This is a heavy diagnosis. Seeking out palliative care early—not just for end-of-life, but as an added quality-of-life and symptom-support service—can provide a safety net for both physical symptoms and emotional distress [19]. You can also connect with reputable rare-disease organizations for resources.
Common questions in this guide
What kind of progression should I expect with AARS2-related leukoencephalopathy?
Can someone with AARS2-related disease have a biological child?
What are the chances that my child will inherit AARS2-related disease?
Should my partner and relatives have AARS2 genetic testing?
When can palliative care help someone with AARS2-related leukoencephalopathy?
What support can help with daily life and caregiving?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on leukoencephalopathy, progressive, with ovarian failure.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our plan for regular 'functional reassessments' to track changes in my memory, movement, and daily independence?
- 2.Can you refer us to a reproductive endocrinologist and preconception team to discuss my fertility options and neurological safety?
- 3.Should my partner and siblings undergo genetic counseling and carrier testing, and what is the process for that?
- 4.At what point should we consider involving a palliative care team to help with symptom management and quality of life?
- 5.Are there reputable rare-disease organizations, like leukodystrophy foundations, where we can connect with other families and resources?
References
References (19)
- 1
The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.
Wade C, de Paiva ARB, Nóbrega PR, et al.
Journal of neurology 2026; (273(7)).
PMID: 42362900 - 2
A novel disease-causing variant associated with a milder phenotype of AARS2-related leukodystrophy - A case report.
Fernandes J, Moura J, Tarrio J, et al.
Molecular genetics and metabolism reports 2024; (41()):101157 doi:10.1016/j.ymgmr.2024.101157.
PMID: 39539319 - 3
Pearls & Oy-sters: AARS2 Leukodystrophy-Tremor and Tribulations.
Green K, MacIver CL, Ebden S, et al.
Neurology 2024; (102(8)):e209296 doi:10.1212/WNL.0000000000209296.
PMID: 38507676 - 4
Expansion of the clinical spectrum associated with AARS2-related disorders.
Srivastava S, Butala A, Mahida S, et al.
American journal of medical genetics. Part A 2019; (179(8)):1556-1564 doi:10.1002/ajmg.a.61188.
PMID: 31099476 - 5
Natural History of Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): A Retrospective Patient Cohort Study.
Hayer SN, McLaren DG, Nance RM, et al.
Neurology and therapy 2026; (15(3)):1269-1292 doi:10.1007/s40120-026-00916-0.
PMID: 41915097 - 6
Disability in Basic Activities of Daily Living Is Associated With Symptom Burden in Older People With Advanced Cancer or Chronic Obstructive Pulmonary Disease: A Secondary Data Analysis.
Fettes L, Bone AE, Etkind SN, et al.
Journal of pain and symptom management 2021; (61(6)):1205-1214 doi:10.1016/j.jpainsymman.2020.10.012.
PMID: 33096219 - 7
Spontaneous conception and successful live birth during hormone replacement therapy in a patient with iatrogenic premature ovarian insufficiency: a case report.
Lee JM, Yang JS, Park JE, et al.
Frontiers in medicine 2026; (13()):1929801 doi:10.3389/fmed.2026.1929801.
PMID: 42712473 - 8
Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency.
Bachelot A, Nicolas C, Bidet M, et al.
Clinical endocrinology 2017; (86(2)):223-228 doi:10.1111/cen.13105.
PMID: 27177971 - 9
ESHRE guideline: female fertility preservation.
, Anderson RA, Amant F, et al.
Human reproduction open 2020; (2020(4)):hoaa052 doi:10.1093/hropen/hoaa052.
PMID: 33225079 - 10
Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI).
La Marca A, Mastellari E
Journal of assisted reproduction and genetics 2021; (38(4)):759-777 doi:10.1007/s10815-021-02067-7.
PMID: 33495935 - 11
Premature ovarian insufficiency and infertility.
Dhanushi Fernando W, Vincent A, Magraith K
Australian journal of general practice 2023; (52(1-2)):32-38 doi:10.31128/AJGP-08-22-6531.
PMID: 36796766 - 12
Family building after diagnosis of premature ovarian insufficiency: a cross-sectional survey in 324 women.
Cambray S, Dubreuil S, Tejedor I, et al.
European journal of endocrinology 2023; (188(3)) doi:10.1093/ejendo/lvad018.
PMID: 36763040 - 13
Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory.
Punj S, Akkari Y, Huang J, et al.
American journal of human genetics 2018; (102(6)):1078-1089 doi:10.1016/j.ajhg.2018.04.004.
PMID: 29754767 - 14
Instability of the mitochondrial alanyl-tRNA synthetase underlies fatal infantile-onset cardiomyopathy.
Sommerville EW, Zhou XL, Oláhová M, et al.
Human molecular genetics 2019; (28(2)):258-268 doi:10.1093/hmg/ddy294.
PMID: 30285085 - 15
Retinopathy and optic atrophy: Expanding the phenotypic spectrum of pathogenic variants in the AARS2 gene.
Peragallo JH, Keller S, van der Knaap MS, et al.
Ophthalmic genetics 2018; (39(1)):99-102 doi:10.1080/13816810.2017.1350723.
PMID: 28820624 - 16
A novel compound heterozygous mutation in AARS2 gene (c.965 G > A, p.R322H; c.334 G > C, p.G112R) identified in a Chinese patient with leukodystrophy involved in brain and spinal cord.
Song C, Peng L, Wang S, Liu Y
Journal of human genetics 2019; (64(10)):979-983 doi:10.1038/s10038-019-0648-7.
PMID: 31388113 - 17
A Systematic Review of Palliative Care Needs in Young-Onset Dementia.
Dang J, Yong ACW, Fong ZH, et al.
Journal of the American Medical Directors Association 2024; (25(10)):105219 doi:10.1016/j.jamda.2024.105219.
PMID: 39155044 - 18
The spectrum of adult-onset heritable white-matter disorders.
Helman G, Venkateswaran S, Vanderver A
Handbook of clinical neurology 2018; (148()):669-692 doi:10.1016/B978-0-444-64076-5.00043-0.
PMID: 29478607 - 19
Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis.
Kavalieratos D, Corbelli J, Zhang D, et al.
JAMA 2016; (316(20)):2104-2114 doi:10.1001/jama.2016.16840.
PMID: 27893131
This page provides information about living with AARS2-related leukoencephalopathy, fertility, and family planning for educational purposes only and does not constitute medical advice. Discuss neurological, reproductive, genetic, and caregiving decisions with your healthcare team.